Zacks Investment Research upgraded shares of Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) from a sell rating to a hold rating in a research note released on Thursday morning.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
Other equities analysts have also recently issued research reports about the stock. ValuEngine raised shares of Isotechnika Pharma from a sell rating to a hold rating in a research report on Friday, February 2nd. BidaskClub raised shares of Isotechnika Pharma from a sell rating to a hold rating in a research report on Thursday, January 25th. Seaport Global Securities reissued a buy rating and set a $11.00 price objective on shares of Isotechnika Pharma in a research report on Friday, March 16th. Royal Bank of Canada assumed coverage on shares of Isotechnika Pharma in a research report on Thursday, February 8th. They set an outperform rating and a $9.00 price objective on the stock. Finally, Cantor Fitzgerald set a $16.00 price objective on shares of Isotechnika Pharma and gave the stock an overweight rating in a research report on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Isotechnika Pharma has an average rating of Buy and an average target price of $10.92.
AUPH stock opened at $5.15 on Thursday. Isotechnika Pharma has a 1 year low of $4.41 and a 1 year high of $8.19.
Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.10. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. Isotechnika Pharma had a negative net margin of 16,855.24% and a negative return on equity of 17.54%. The business’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.11) EPS. equities analysts expect that Isotechnika Pharma will post -0.7 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its holdings in shares of Isotechnika Pharma by 13,197.5% in the 3rd quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 26,395 shares during the last quarter. Spark Investment Management LLC acquired a new stake in shares of Isotechnika Pharma in the 4th quarter worth about $153,000. Cutler Capital Management LLC raised its holdings in shares of Isotechnika Pharma by 25.0% in the 4th quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 10,000 shares during the last quarter. Swiss National Bank acquired a new stake in shares of Isotechnika Pharma in the 4th quarter worth about $421,000. Finally, Kazazian Asset Management LLC raised its holdings in shares of Isotechnika Pharma by 11.6% in the 4th quarter. Kazazian Asset Management LLC now owns 156,126 shares of the biotechnology company’s stock worth $707,000 after acquiring an additional 16,189 shares during the last quarter. Institutional investors own 28.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/09/isotechnika-pharma-auph-raised-to-hold-at-zacks-investment-research.html.
Isotechnika Pharma Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Get a free copy of the Zacks research report on Isotechnika Pharma (AUPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.